High-strength medicine-carrying gel embolism microsphere capable of loading thrombin

The target of gel embolization microspheres in the treatment of hypertrophic cardiomyopathy in the prior art was solved by using gel microspheres composed of polyacrylamide-polyacrylic acid copolymer, zwitterionic polymer and cyclopeptide functionalized chitosan. The problem of insufficient drug loading and sustained release has achieved efficient thrombin loading and sustained release, and improved the therapeutic effect.

CN118903525APending Publication Date: 2024-11-08HUNAN UNIV OF TECH
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202410835052.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-06-26
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing gel embolization microspheres have problems with insufficient targeted drug loading and sustained release in the treatment of hypertrophic cardiomyopathy, especially while maintaining good mechanical properties and biocompatibility, it is difficult to achieve effective drug loading and relaxation. release.

Method used

High-strength gel microspheres composed of polyacrylamide-polyacrylic acid copolymer, zwitterionic polymer and cyclic peptide functionalized chitosan were prepared by reverse phase emulsion method or microfluidic control method to achieve drug loading and sustained release , has good mechanical properties and morphological stability.

Benefits of technology

It achieves efficient loading and stable sustained release of thrombin, improves the effect of hypertrophic cardiomyopathy treatment, and ensures good embolization effect and biocompatibility.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903525A_ABST
    Figure CN118903525A_ABST
Patent Text Reader

Abstract

The invention discloses a high-strength embolization gel microsphere capable of loading thrombin, which is characterized in that a microsphere main body is composed of a PAAm-PAAc copolymer, a zwitterionic macromolecule and cyclopeptide functionalized chitosan, and can be prepared through reverse emulsion polymerization or microfluidic. Due to the special structure, charges and groups in the microspheres, the microspheres have excellent strength, can resist compression, can load a large amount of thrombin and realize effective slow release, can be used as an embolism agent to be applied to interventional therapy of hypertrophic cardiomyopathy and other diseases, and can also be mixed with other dressings to be applied to the field of trauma treatment.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to gel embolic microspheres and a preparation method thereof, and in particular to gel embolic microspheres which have excellent mechanical properties, are stable in shape, can be loaded with a large amount of drugs such as thrombin and achieve sustained release, and a preparation method thereof. Background Art

[0002] Hypertrophic cardiomyopathy is one of the main causes of sudden cardiac death. For patients with poor drug control, percutaneous septal myocardial ablation (ASA) has gradually become an alternative treatment to surgery. However, the anhydrous alcohol ablation agent currently used is uncontrollable after being injected into the target blood vessel, and often leaks or flows into other coronary arteries, leading to serious consequences such as myocardial infarction or conduction system damage in non-target ablation sites. Therefore, anhydrous alcohol is not an ideal ASA ablation agent.

[0003] In recent years, non-alcoholic septal ablation has become a research hotspot in the field of interventional treatment of hypertrophic obstructive cardiomyopathy (HOCM), and thorough embolization has become a guarantee for successful treatment. At present, there have been single-center, small-sample studies using microcoils, gelatin sponges or polymer particles, cyanoacrylate adhesives and other media for physical or chemical ablation. The conclusions are generally believed to have good perioperative safety, but whether the above media can achieve the same effectiveness as alcohol ablation needs further verification. In recent years, the use of embolic microsphere ablative agents or embolic agents to achieve interventional treatment has also become a very popular treatment method. How to combine drugs and devices to achieve thorough embolization has become the key to the performance of such devices. Thrombin can effectively solidify blood and enhance the embolization effect, but thrombin itself is unstable and is easily inactivated when encountering acid, alkali, heavy metals or high temperature. It cannot be used alone. If special microspheres can be effectively loaded, the combined effect of the two will be effectively exerted.

[0004] In the field of gel embolic microspheres, a large number of studies have focused on the field of vascular embolization. Various types of PVA and sodium alginate microspheres have been developed and applied, and a small number of products have appeared, such as the Mindray microsphere series. However, the targeted drug loading and sustained release of microspheres are still a challenge that needs to be overcome, especially the need to have good mechanical properties and biocompatibility at the same time, which puts higher requirements on the design of the material itself.

[0005] In view of the above problems, the present invention has developed a new type of gel embolic microspheres, which can not only meet the basic mechanical property requirements and not cause mechanical property changes during the embolization process, but also can load a large amount of thrombin and achieve sustained release, which will greatly improve the therapeutic effect of HOCM. Summary of the invention

[0006] The present invention aims to solve at least one of the technical problems existing in the above-mentioned prior art. To this end, the present invention provides a gel microsphere having good mechanical properties, stable morphology, and capable of loading a large amount of thrombin and achieving stable long-term sustained release to ensure a good embolization effect.

[0007] The microspheres are made by the following technologies: A high-strength embolic gel microsphere capable of loading thrombin, the main body of which is composed of the following main substances and their corresponding mass relationships: Polyacrylamide-polyacrylic acid copolymer 100 Zwitterionic polymer 20-50 Cyclic peptide functionalized chitosan 3-8 Furthermore, in the polyacrylamide-polyacrylic acid copolymer (PAAm-PAAc), the molar ratio of acrylamide (AAm) and acrylic acid (AAc) segments is between 0.6:1-1:2, PAAm-PAAc is cross-linked in the gel by a cross-linking agent N'N-methylenebisacrylamide (BIS), the molar amount of the cross-linking agent is between 2-4% of the sum of the AAm and AAc monomer amounts, and the Zeta potential of the pure polymer is between -30mV and -65mV.

[0008] Furthermore, the zwitterionic polymer is one of polymethacrylate sulfobetaine, polymethacryloylethyl sulfobetaine, polymethacrylate carboxybetaine, polymethyl acrylate cysteine, and polymethyl acrylate serine, and its molecular weight is between Mw=50-100 kDa.

[0009] The molecular structure of the polymethyl acrylate cysteine ​​is as follows:

[0010] The molecular structure of the polymethylacrylate serine is as follows:

[0011] Furthermore, the cyclic peptide functionalized chitosan is to insert the cyclic peptide into the chitosan macromolecular chain for modification, and the cyclic peptide can be a polycyclic peptide and its derivatives, preferably, the polycyclic peptide is a five-membered cyclic peptide.

[0012] Furthermore, the mass of the cyclic peptide is between 20-40% of the mass of chitosan; the molecular weight of the cyclic peptide functionalized chitosan is between Mw=50-120 kDa.

[0013] Furthermore, the five-membered cyclic peptide is composed of arginine, glycine, aspartic acid, D-phenylalanine, and lysine, and the first and last amide bonds form a ring, and its molecular structure is as follows:

[0014] Furthermore, the polycyclic peptide derivative may be one of cyclic peptide-polyethylene glycol-folic acid and cyclic peptide-polyethylene glycol-amino.

[0015] Furthermore, the five-membered cyclic peptide modified chitosan-based macromolecule can be directly purchased as a commercial product, or can be connected by reactions of amino groups in chitosan such as condensation, Schiff base reaction, modified thiolation reaction, etc. It can also be synthesized by improving the method described in invention patent 201811542507.4 according to actual proportions and needs, as follows: Take aminopolyethylene glycol 2000 and dissolve it in a small amount of anhydrous dimethyl sulfoxide. According to the molar ratio of aminopolyethylene glycol 2000: disuccinimide of 1:2, take disuccinimide and dissolve it in an appropriate amount of anhydrous dimethyl sulfoxide. Slowly add the dimethyl sulfoxide solution of disuccinimide to the dimethyl sulfoxide solution of polyethylene glycol 2000, stir at room temperature for 2 to 9 hours, and obtain reaction solution 1. According to the molar ratio of polyethylene glycol 2000: cyclopeptide of 1:1, take cyclopeptide and dissolve it in an appropriate amount of anhydrous dimethyl sulfoxide to prepare a reaction solution with a concentration of 5 .0mg / mL solution, slowly add the anhydrous dimethyl sulfoxide solution of cyclopeptide to reaction solution 1, stir at room temperature for 1 to 12 hours to obtain reaction solution 2, take chitosan according to the molar ratio of free amino group on chitosan: cyclopeptide of 3:1 to 20:1, slowly add reaction solution 2 to the weak acid aqueous solution of chitosan, stir at room temperature for 1 to 24 hours, place the final reaction solution in a dialysis bag with a molecular weight cutoff of 4000, dialyze with distilled water for 48 hours, and freeze-dry to obtain a cyclopeptide-chitosan modified product.

[0016] Furthermore, the ion molar ratio of cationic groups and anionic groups carried by all molecular chains in the gel is between 1.2 and 2.5; the increase of anions is beneficial to the swelling of the gel and provides polar points for drug-loaded thrombin.

[0017] Furthermore, the pore size of the gel is affected by the material ratio, polymer composition and internal charge ratio, and the pore diameter is between 50-500 μm.

[0018] Furthermore, the preparation methods of the gel include an inverse emulsion method and a microfluidics method.

[0019] Further, the preparation process of the inverse emulsion method is: I: dissolving monomers acrylamide, acrylic acid, crosslinking agent N'N-methylenebisacrylamide and photoinitiator in water to form a uniform solution A, wherein the amount of photoinitiator is between 0.2% and 0.5% of the mass of the monomer, and the mass concentration of the solvent is between 10% and 20%; II: Add zwitterionic polymer and cyclopeptide functionalized chitosan solution to solution A, and stir evenly to form an aqueous prepolymer solution; the mass concentration of the cyclopeptide functionalized chitosan solution is between 10-20%, and the solution is a mixture of DMSO and water, and the volume ratio of the two is between 1:3-1:6; III: Add the water phase prepolymer into the oil phase liquid with a volume 3-5 times of the volume, stir at 200-600rmp to form 50-800um microspheres in the oil phase, and add alkali solution to adjust the pH value of the system to between 9.5-10.5; The oil phase liquid is composed of low-viscosity oils and surfactants, and the mass concentration of the surfactant is between 0.5-1.5% of the oils; IV: irradiating the microsphere suspension system in III with ultraviolet light of a certain wavelength, continuously stirring and irradiating for 2-4 hours to obtain gel microspheres; V: The gel microspheres are continuously immersed in pure water for purification, the DMSO solvent in the microspheres is removed and the pH value is adjusted to neutral to obtain the final microsphere product.

[0020] Further, the preparation process of the microfluidic is: a: dissolving monomers acrylamide, acrylic acid, crosslinking agent N'N-methylenebisacrylamide, zwitterionic polymer, cyclopeptide functionalized chitosan, and photoinitiator in a mixture of DMSO and water to obtain an aqueous prepolymer solution, wherein the volume ratio of DMSO to water is between 1:5 and 1:10; b: Low-viscosity oil containing surfactant is used as the oil phase; the concentration of surfactant in the oil phase is between 20-40g / L; c: The aqueous prepolymer solution and the oil phase are introduced into the microfluidic chip respectively, and the flow rate of the oil phase is controlled to be 20-80 μL / min and the flow rate of the aqueous phase is controlled to be 2-8 μL / min; d: Using an alkaline liquid with a pH between 9.5 and 10.5 as a receiving liquid, introducing the outflowing microspheres into the receiving liquid and continuously stirring at a speed of 150-300 rpm for 2-4 hours, and continuously irradiating with ultraviolet light of a certain wavelength to obtain gel microspheres; e: The gel microspheres are continuously immersed in pure water for purification, the DMSO solvent in the microspheres is removed and the pH value is adjusted to neutral to obtain the final microsphere product.

[0021] Furthermore, the viscosity of the low-viscosity oil is between 100-1000cp, including one of hexadecane, liquid paraffin, mineral oil, isopropyl palmitate, methyl silicone oil, and methylphenyl silicone oil AR-20; the surfactant includes one of Span80, polyglycerol ricinoleate PGPR, Tween 20, sodium dodecyl sulfate SDS, and hexadecyltrimethylammonium bromide CTAB, and the HLB value is between 12-42.

[0022] Further, preferably, the low viscosity oils are methylphenyl silicone oil AR-20 and liquid paraffin; the surfactants are Span 80 and cetyltrimethylammonium bromide CTAB.

[0023] Furthermore, the polypeptide-modified chitosan solution can be an aqueous solution, a water / DMSO mixed solution or a DMSO solution according to the characteristics of the macromolecule. If a DMSO solution is added, the gel needs to be repeatedly immersed and washed after formation to remove the DMSO.

[0024] Furthermore, the photoinitiator is one of photoinitiator I2959 and photoinitiator 1173, and the corresponding ultraviolet irradiation wavelengths are 365nm and 320nm.

[0025] Furthermore, the microspheres can be loaded with thrombin in the aqueous prepolymer solution during the preparation process, with the loading concentration reaching 50 mg / ml, and can achieve a sustained release for 6-12 days.

[0026] Furthermore, the thrombin has various types and molecular weights; preferably, the thrombin in the present invention is a small molecule thrombin, which is a commercially available product with CAS number: 9002-04-4 and a molecular structure as follows:

[0027] Furthermore, the microspheres can achieve the above good mechanical properties, suitable elasticity and high thrombin loading efficiency, which is due to their special molecular structure including gel pore structure, the chain length of non-crosslinked macromolecules, the ratio of each charge in the molecule and the polypeptide groups therein. Among them, the appropriate polymer crosslinking density and molecular weight can adjust the gel pore size, the appropriate non-binding charge is conducive to regulating the swelling control of the gel, and the appropriate non-crosslinked macromolecules, the zwitterionic polymers and polypeptide-modified chitosan contained in this penalty exist as isolated chains, which can penetrate several pore structures, and can effectively achieve the enhancement of gel and the improvement of modulus; at the same time, the excess cationic groups in the gel network can be conducive to its binding with thrombin having negative charge groups, and the polypeptide groups introduced by chitosan modification also play a role in further increasing its binding with thrombin, and can also provide a certain binding with the blood vessel wall.

[0028] Furthermore, the equilibrium swelling ratio of the microspheres is between 220% and 360% based on the mass of the gel dry spheres.

[0029] Furthermore, the particle size that can be prepared can be between 50-800 μm, and different model sizes can be set after screening according to the particle size, which can be limited to 100 μm.

[0030] Furthermore, the microspheres can withstand a compression deformation between 40-75%, and the maximum pressure they can withstand is 20-40 KPa. If the pressure exceeds the limit, the microspheres cannot recover their shape and are easily broken. Within the compression limit, the microspheres can recover their shape.

[0031] Further, the performance testing method of the microspheres includes: The compression ratio of the microspheres was tested using a hydrogel microsphere parallel plate compression tester to test the compression deformation rate and stress.

[0032] The loading concentration of thrombin added by the microspheres was calculated, and the released concentration was tested by UV spectroscopy, with the peak near 280 nm as the characteristic peak, to test the enzyme concentration in the solution after release. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 This is the appearance of the drug-loaded embolic microspheres prepared in Example 1; Figure 2 This is the in vitro release graph of thrombin from the drug-loaded embolus prepared in Example 1. DETAILED DESCRIPTION

[0034] The embodiments of the present application will be described in detail below in conjunction with examples, but those skilled in the art will understand that the following examples are only used to illustrate the present application and should not be construed as limiting the scope of the present application. Example 1

[0035] A high-strength embolic gel microsphere capable of loading thrombin, the main body of which is composed of the following main components and corresponding mass proportions: PAAm-PAAc copolymer 100 Zwitterionic polymer 32 Cyclic peptide functionalized chitosan 6.5 In the PAAm-PAAc copolymer, the molar ratio of AAm to AAc is 1.4. The PAAm-PAAc copolymer is cross-linked in the gel by a cross-linking agent BIS. The molar amount of the cross-linking agent BIS is 3% of the sum of the monomer amounts of AAm and AAc. The Zeta potential of the pure polymer is -44 mV.

[0036] The zwitterionic polymer is polymethacrylate carboxybetaine, and its molecular weight Mw=65.5 kDa, Its molecular structure is as follows:

[0037] The cyclic peptide functionalized chitosan is a five-membered cyclic peptide functionalized chitosan, and its molecular weight is Mw=82 kDa; The five-membered cyclic peptide is composed of arginine, glycine, aspartic acid, D-phenylalanine, and lysine, and the first and last amide bonds form a ring, and its molecular structure is as follows:

[0038] The cyclic peptide functionalized chitosan is synthesized by the method described in the invention patent 201811542507.4 and improved according to the actual proportion and requirements, as follows: Take aminopolyethylene glycol 2000 and dissolve it in a small amount of anhydrous dimethyl sulfoxide. According to the molar ratio of aminopolyethylene glycol 2000: disuccinimide being 1:2, take disuccinimide and dissolve it in an appropriate amount of anhydrous dimethyl sulfoxide. Slowly add the dimethyl sulfoxide solution of disuccinimide to the dimethyl sulfoxide solution of polyethylene glycol 2000, and stir at room temperature for 5 hours to obtain reaction solution 1. According to the molar ratio of polyethylene glycol 2000: cyclopeptide being 1:1, take the cyclopeptide and dissolve it in an appropriate amount of anhydrous dimethyl sulfoxide to prepare The concentration of the solution is 5.0 mg / mL, the anhydrous dimethyl sulfoxide solution of the cyclopeptide is slowly added to the reaction solution 1, stirred at room temperature for 6 hours, and the reaction solution 2 is obtained. Chitosan is taken according to the molar ratio of free amino groups on chitosan: cyclopeptide of 14:1, and the reaction solution 2 is slowly added to the weak acid aqueous solution of chitosan, stirred at room temperature for 12 hours, and the final reaction solution is placed in a dialysis bag with a molecular weight cutoff of 4000, dialyzed with distilled water for 48 hours, and freeze-dried to obtain the cyclopeptide-chitosan modified product.

[0039] The ion molar ratio of the cationic groups and the anionic groups carried by all molecular chains in the gel is 1.6.

[0040] The preparation method of the gel is the reverse emulsion method, and the preparation process is as follows: I: Dissolve monomers AAm, AAc, crosslinker BIS and photoinitiator I2959 in water to form a uniform solution A. The amount of photoinitiator used is between 0.4% of the monomer mass and the mass concentration of the solution is 15%; II: Add zwitterionic polymer and cyclopeptide functionalized chitosan solution to solution A, stir evenly to form an aqueous prepolymer solution; the mass concentration of the cyclopeptide functionalized chitosan solution is 12%, and the solution is a mixture of DMSO and water, and the volume ratio of the two is 1:4; III: Add the water phase prepolymer liquid into the oil phase liquid with a volume 4 times that of the water phase prepolymer liquid and a viscosity of 650cp, stir at 300rmp to form 200-400μm microspheres in the oil phase, and add alkali solution to adjust the pH value of the system to between 9.5-10.5; The oil phase liquid is composed of liquid paraffin and surfactant Span 80, and the mass concentration of Span 80 is 0.9% of the liquid paraffin; IV: After stirring into balls, the microsphere suspension system is irradiated with ultraviolet light of 360 nm wavelength, and stirring and irradiation are continued for 3 hours to obtain gel microspheres.

[0041] V: The gel microspheres are continuously immersed in pure water for purification, the DMSO solvent in the microspheres is removed and the pH value is adjusted to neutral to obtain the final microsphere product.

[0042] The microspheres can be loaded with thrombin in the aqueous prepolymer solution during the preparation process, and can achieve a 9-day sustained release, and the release curve is as follows: Figure 2 shown.

[0043] The equilibrium swelling ratio of the microspheres is 320% based on the mass of the gel dry spheres.

[0044] The particle size of the final microsphere product is between 80-400 μm, and different models can be set according to the particle size: 80-150 μm, 180-240 μm, 200-320 μm, 300-400 μm.

[0045] The microspheres can withstand a compression deformation of 65% and a maximum pressure of 32 KPa.

[0046] Example 2 A high-strength embolic gel microsphere capable of loading thrombin, the main body of which is composed of the following main components and corresponding mass proportions: PAAm-PAAc copolymer 100 Zwitterionic polymer 40 Cyclic peptide functionalized chitosan 4.5 In the PAAm-PAAc copolymer, the molar ratio of AAm to AAc is 1.6. The PAAm-PAAc copolymer is cross-linked in the gel by a cross-linking agent BIS. The molar amount of the cross-linking agent BIS is 3.5% of the sum of the monomer amounts of AAm and AAc. The Zeta potential of the pure polymer is -34 mV.

[0047] The zwitterionic polymer is polymethacrylate carboxybetaine, and its molecular weight Mw=82 kDa, Its molecular structure is as follows:

[0048] The cyclic peptide functionalized chitosan is five-membered cyclic peptide-polyethylene glycol-amino modified chitosan.

[0049] The five-membered cyclic peptide-polyethylene glycol-amino is a commercially available product, which can be selected from Shenzhen Meiluo Technology Co., Ltd., and its molecular structure is as follows:

[0050] The mass of the five-membered cyclic peptide-polyethylene glycol-amino group is 22% of the mass of chitosan; the molecular weight Mw of the chitosan modified by the cyclic peptide functionalized chitosan is 82 kDa.

[0051] The five-membered cyclic peptide-polyethylene glycol-amino functionalized chitosan is prepared by the method described in invention patent 201811542507.4, and only the cyclic peptide is replaced by the five-membered cyclic peptide-polyethylene glycol-amino group.

[0052] The ion molar ratio of the cationic groups and the anionic groups carried by all molecular chains in the gel is 1.4.

[0053] The preparation method of the gel is the reverse emulsion method, and the preparation process is as follows: I: Dissolve monomers AAm, AAc, crosslinker BIS and photoinitiator I2959 in water to form a uniform solution A. The amount of photoinitiator used is between 0.35% of the monomer mass and the mass concentration of the solution is 18%; II: Add zwitterionic polymer and cyclopeptide functionalized chitosan solution to solution A, stir evenly to form an aqueous prepolymer solution; the mass concentration of the cyclopeptide functionalized chitosan solution is 16%, and the solution is a mixture of DMSO and water, and the volume ratio of the two is 1:5; III: Pour the water phase prepolymer into an oil phase liquid with a volume 3.5 times that of the water phase prepolymer and a viscosity of 800cp, stir at 400rmp to form microspheres of 100-250μm in the oil phase, and add alkali solution to adjust the pH value of the system to 10.2; The oil phase is composed of methylphenyl silicone oil AR-20 and surfactant polyglycerol ricinoleate PGPR, and the mass concentration of polyglycerol ricinoleate PGPR is 0.9% of methylphenyl silicone oil AR-20. IV: After stirring into balls, the microsphere suspension system is irradiated with ultraviolet light of 360 nm wavelength, and stirring and irradiation are continued for 3.5 hours to obtain gel microspheres.

[0054] V: The gel microspheres are continuously immersed in pure water for purification, the DMSO solvent in the microspheres is removed and the pH value is adjusted to neutral to obtain the final microsphere product.

[0055] During the preparation process, the microspheres can be loaded with thrombin in the aqueous prepolymer solution, and a 10-day sustained release can be achieved.

[0056] The equilibrium swelling ratio of the microspheres is 285% based on the mass of the gel dry spheres.

[0057] The particle size of the final microsphere product that can be prepared is between 80-240 μm, and different models can be set according to the particle size: 80-120 μm, 120-180 μm, and 160-240 μm.

[0058] The microspheres can withstand a compression deformation of 72% and a maximum pressure of 29 KPa.

[0059] Example 3 A high-strength embolic gel microsphere capable of loading thrombin, the main body of which is composed of the following main components and corresponding mass proportions: PAAm-PAAc copolymer 100 Zwitterionic polymer 26.5 Cyclic peptide functionalized chitosan 7.5 In the PAAm-PAAc copolymer, the molar ratio of AAm to AAc is 0.9, the PAAm-PAAc copolymer is cross-linked by a cross-linking agent BIS, the molar amount of the cross-linking agent BIS is 3.2% of the sum of the monomer amounts of AAm and AAc, and the Zeta potential of the pure polymer is -58 mV.

[0060] The zwitterionic polymer is polymethyl acrylate cysteine, with a molecular weight Mw=60 kDa and a molecular structure as follows:

[0061] The cyclic peptide functionalized chitosan is five-membered cyclic peptide modified chitosan.

[0062] The mass of the five-membered cyclic peptide is 32% of the mass of chitosan; the molecular weight Mw of the five-membered cyclic peptide-modified chitosan is 68 kDa.

[0063] The five-membered cyclic peptide is composed of arginine, glycine, aspartic acid, D-phenylalanine, and lysine, and the first and last amide bonds form a ring, and its molecular structure is as follows:

[0064] The cyclic peptide modified chitosan-based macromolecule is a commercially available product, which can be purchased from Shenzhen Meiluo Technology.

[0065] The ion molar ratio of the cationic groups and the anionic groups carried by all molecular chains in the gel is 1.7.

[0066] Further, the preparation process of the microfluidic is: a: Dissolve monomers AAm, AAc, BIS, polymethyl acrylate cysteine, cyclopeptide functionalized chitosan, and photoinitiator 1173 in a DMSO / water mixture to obtain an aqueous prepolymer solution, wherein the volume ratio of DMSO to water is 1:8; b: 400cp viscosity liquid paraffin containing surfactant Tween 20 is used as the oil phase; the concentration of Tween 20 in the liquid paraffin is 35g / L; c: The aqueous prepolymer solution and the oil phase were introduced into the microfluidic chip respectively, and the flow rate of the oil phase was controlled to be 45 μL / min and the flow rate of the aqueous phase was controlled to be 6.8 μL / min; d: Using an alkaline liquid with a pH of 10.2 as the receiving liquid, introducing the outflowing microspheres into the receiving liquid and continuously stirring at a speed of 400 rpm for 3 hours, and continuously irradiating with 320 nm ultraviolet light to obtain gel microspheres; e: The gel microspheres are continuously immersed in pure water for purification, the DMSO solvent in the microspheres is removed and the pH value is adjusted to neutral to obtain the final microsphere product.

[0067] During the preparation process, the microspheres can be loaded with thrombin in the aqueous prepolymer solution, and a 9-day sustained release can be achieved.

[0068] The equilibrium swelling ratio of the microspheres is 245% based on the mass of the gel dry spheres.

[0069] The particle size that can be prepared is between 150-300 μm, and different models can be set according to the particle size: 150-220 μm, 220-300 μm.

[0070] The microspheres can withstand a compression deformation of 72% and a maximum pressure of 29 KPa.

[0071] Example 4 A high-strength embolic gel microsphere capable of loading thrombin, the main body of which is composed of the following main components and corresponding mass proportions: PAAm-PAAc copolymer 100 Zwitterionic polymer 46.5 Cyclic peptide functionalized chitosan 3.8 In the PAAm-PAAc copolymer, the molar ratio of AAm to AAc is 1.9, the PAAm-PAAc copolymer is cross-linked by a cross-linking agent BIS, the molar amount of the cross-linking agent BIS is 3.8% of the sum of the monomer amounts of AAm and AAc, and the Zeta potential of the pure polymer is -31 mV.

[0072] The zwitterionic polymer is polymethyl acrylate serine, with a molecular weight Mw=85kDa and a molecular structure as follows:

[0073] The cyclic peptide functionalized chitosan is five-membered cyclic peptide modified chitosan, the mass of the five-membered cyclic peptide is 35% of the mass of chitosan; the molecular weight Mw of the five-membered cyclic peptide modified chitosan is 102 kDa.

[0074] The five-membered cyclic peptide is composed of arginine, glycine, aspartic acid, D-phenylalanine, and lysine, and the first and last amide bonds form a ring, and its molecular structure is as follows:

[0075] The cyclic peptide modified chitosan-based macromolecule is a commercially available custom product, which can be purchased from Shenzhen Meiluo Technology.

[0076] The ion molar ratio of the cationic groups and the anionic groups carried by all molecular chains in the gel is 2.1.

[0077] Further, the preparation process of the microfluidic is: a: Dissolve monomers AAm, AAc, BIS, polymethyl acrylate cysteine, cyclic peptide functionalized chitosan, and photoinitiator 1173 in a DMSO / water mixture to obtain an aqueous prepolymer solution, wherein the volume ratio of DMSO to water is 1:6; b: 400cp viscosity liquid paraffin containing surfactant Tween 20 is used as the oil phase; the concentration of Tween 20 in the liquid paraffin is 35g / L; c: The aqueous prepolymer solution and the oil phase were introduced into the microfluidic chip respectively, and the flow rate of the oil phase was controlled to be 65 μL / min and the flow rate of the aqueous phase was controlled to be 5.5 μL / min; d: Using an alkaline liquid with a pH of 10.6 as a receiving liquid, introducing the outflowing microspheres into the receiving liquid and continuously stirring at a speed of 250 rpm for 3.5 hours, and continuously irradiating with 320 nm ultraviolet light to obtain gel microspheres; e: The gel microspheres are continuously immersed in pure water for purification, the DMSO solvent in the microspheres is removed and the pH value is adjusted to neutral to obtain the final microsphere product.

[0078] During the preparation process, the microspheres can be loaded with thrombin in the aqueous prepolymer solution, and a 9-day sustained release can be achieved.

[0079] The equilibrium swelling ratio of the microspheres is 245% based on the mass of the gel dry spheres.

[0080] The particle size that can be prepared is between 400-600 μm, and different models can be set according to the particle size: 400-450 μm, 500-600 μm.

[0081] The microspheres can withstand a compression deformation of 78% and a maximum pressure of 35 KPa.

Claims

1. A high-strength embolic gel microsphere capable of loading thrombin, the main body of which is composed of the following main substances and their corresponding mass relationships: Polyacrylamide-polyacrylic acid copolymer 100 Zwitterionic polymer 20-50 Cyclic peptide functionalized chitosan 3-8.

2. The high-strength embolic gel microspheres capable of loading thrombin as claimed in claim 1, It is characterized in that In the polyacrylamide-polyacrylic acid copolymer, the molar ratio of acrylamide to acrylic acid segments is between 0.6:1 and 1:2, the polyacrylamide-polyacrylic acid copolymer is cross-linked in the gel by a cross-linking agent N'N-methylenebisacrylamide, the molar amount of the cross-linking agent is between 2% and 4% of the sum of the acrylamide and acrylic acid monomers, and the Zeta potential of the pure polyacrylamide-polyacrylic acid copolymer is between -30mV and -65mV.

3. The high-strength embolic gel microspheres capable of loading thrombin as claimed in claim 1, It is characterized in that The zwitterionic polymer is one of polymethacrylate sulfobetaine, polymethacryloylethyl sulfobetaine, polymethacrylate carboxybetaine, polymethyl acrylate cysteine ​​and polymethyl acrylate serine, and its molecular weight is between Mw=50-100 kDa.

4. The high-strength embolic gel microspheres capable of loading thrombin as claimed in claim 1, It is characterized in that The cyclic peptide functionalized chitosan is to insert the cyclic peptide into the chitosan macromolecular chain for modification. The cyclic peptide can be a polycyclic peptide and its derivatives. Preferably, the polycyclic peptide is a five-membered cyclic peptide.

5. The high-strength embolic gel microspheres capable of loading thrombin as claimed in claim 1, It is characterized in that The ion molar ratio of the cationic groups and the anionic groups carried by all molecular chains in the gel is between 1.2 and 2.

5.

6. The high-strength embolic gel microsphere capable of loading thrombin as claimed in claim 1, It is characterized in that The preparation methods of the gel include reverse emulsion method and microfluidics method.

7. The high-strength embolic gel microsphere capable of loading thrombin as claimed in claim 1, It is characterized in that The preparation process of the inverse emulsion method is: I: dissolving monomers acrylamide, acrylic acid, crosslinking agent N'N-methylenebisacrylamide and photoinitiator in water to form a uniform solution A, wherein the amount of photoinitiator is between 0.2% and 0.5% of the mass of the monomer, and the mass concentration of the solvent is between 10% and 20%; II: Add zwitterionic polymer and cyclopeptide functionalized chitosan solution to solution A, and stir evenly to form an aqueous prepolymer solution; the mass concentration of the cyclopeptide functionalized chitosan solution is between 10-20%, and the solution is a mixture of DMSO and water, and the volume ratio of the two is between 1:3-1:6; III: Add the water phase prepolymer liquid into the oil phase liquid with a volume 3-5 times of the volume, stir at 200-600rmp to make the water phase prepolymer liquid form microspheres in the oil phase, and add alkali solution to adjust the pH value of the system to between 9.5-10.5; The oil phase liquid is composed of low-viscosity oils and surfactants, and the mass concentration of the surfactant is between 0.5-1.5% of the oils; IV: irradiating the microsphere suspension system in III with ultraviolet light of a certain wavelength, continuously stirring and irradiating for 2-4 hours to obtain gel microspheres; V: The gel microspheres are continuously immersed in pure water for purification, the DMSO solvent in the microspheres is removed and the pH value is adjusted to neutral to obtain the final microsphere product.

8. The high-strength embolic gel microspheres with coagulation function as claimed in claim 1, It is characterized in that The microfluidic preparation process is: a: dissolving monomers acrylamide, acrylic acid, crosslinking agent N'N-methylenebisacrylamide, zwitterionic polymer, cyclopeptide functionalized chitosan, and photoinitiator in a mixture of DMSO and water to obtain an aqueous phase prepolymer solution, wherein the volume ratio of DMSO to water is between 1:5 and 1:10; b: Low-viscosity oil containing surfactant is used as the oil phase; the concentration of surfactant in the oil phase is between 20-40g / L; c: The aqueous prepolymer solution and the oil phase are introduced into the microfluidic chip respectively, and the flow rate of the oil phase is controlled to be 20-80 μL / min and the flow rate of the aqueous phase is controlled to be 2-8 μL / min; d: Using an alkaline liquid with a pH between 9.5 and 10.5 as a receiving liquid, introducing the outflowing microspheres into the receiving liquid and continuously stirring at a speed of 150-300 rpm for 2-4 hours, and continuously irradiating with ultraviolet light of a certain wavelength to obtain gel microspheres; e: The gel microspheres are continuously immersed in pure water for purification, the DMSO solvent in the microspheres is removed and the pH value is adjusted to neutral to obtain the final microsphere product.

9. The high-strength embolic gel microspheres with coagulation function as described in claims 7 and 8, It is characterized in that The viscosity of the low-viscosity oil is between 100-1000cp, and includes one of hexadecane, liquid paraffin, mineral oil, isopropyl palmitate, methyl silicone oil, and methylphenyl silicone oil AR-20; the surfactant includes one of Span 80, polyglycerol ricinoleate PGPR, Tween 20, sodium dodecyl sulfate SDS, and hexadecyltrimethylammonium bromide CTAB, and the HLB value is between 16-42.

10. The high-strength embolic gel microspheres with coagulation function as claimed in claims 7 and 8, It is characterized in that During the preparation process, the microspheres can be loaded with thrombin in the aqueous prepolymer solution, with a loading concentration of up to 50 mg / mL, and can achieve a sustained release for 6-12 days.

Citation Information

Cited By

  • Strontium-doped polypeptide hydrogel, preparation method, composite biological scaffold and application

    CN122342858A